Pharvaris N.V. PHVS
34.78 USD +1.25 (+3.73%)
At closeNov 4, 2026, 4:11 AM EST
35.00 +0.22 +0.63%
Pre-market · Nov 4, 4:11 AM ET
33.90 Day range 35.30
21.02 52-week range 43.25
- YTD
- +25.33%
- 1 year
- +60.72%
- Market cap
- 2.44B
- EPS (ttm)
- -3.06
- Shares out
- 70.20M
- Forward P/E
- -11.38
- YTD return
- +25.33%
- 1-year return
- +60.72%
- Volume
- 577.20K
- Avg volume
- 813.04K
- Open
- 33.90
- Previous close
- 33.53
- Day's range
- 33.90 – 35.30
- 52-week range
- 21.02 – 43.25
- Beta
- -2.52
- Analysts
- Strong Buy
- Price target
- 57.63 (+65.7%)
- Earnings date
- Nov 11, 2026
2Y +10.89 (+45.51%)
Key statistics
- Enterprise value
- 2.04B
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 7.22
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -90.36M
- Total cash
- 318.28M
- Total debt
- 673.73K
- Return on equity
- -70.46%
- Short % of float
- 4.26%
- 50-day average
- 33.61
- 200-day average
- 31.03
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 57.63 +65.7% upside
Now 34.78
- Target (low)
- 40.99
- Target (mean)
- 57.63
- Target (high)
- 78.98
Ratings (0m) 14 14 buy · 0 hold · 0 sell
- Strong buy3
- Buy11
- Hold0
- Sell0
- Strong sell0
Next earnings
Nov 11, 2026
Expected Nov 11, 2026. Consensus EPS estimate -0.71909.
Financials — quick view
PHVS Revenue — quarterly 0
PHVS Net income — quarterly -47.84M
PHVS EPS — quarterly -0.70
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 11, 2026 | Sep 30, 2026 | -0.81867 | — | — | — |
| Aug 12, 2026 | Jun 30, 2026 | -0.7467 | -0.81 | -0.06 | -8.48% |
| May 12, 2026 | Mar 31, 2026 | -0.82187 | -0.70 | +0.12 | +14.83% |
| Apr 2, 2026 | Dec 31, 2025 | -0.71462 | -0.84565 | -0.13 | -18.34% |
| Nov 12, 2025 | Sep 30, 2025 | -0.78 | -0.70 | +0.08 | +10.26% |
| Aug 12, 2025 | Jun 30, 2025 | -0.87 | -0.94 | -0.07 | -8.05% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 23, 2026 | B of A Securities | up | Neutral | Buy |
| Sep 10, 2026 | Guggenheim | main | Buy | Buy |
| Sep 9, 2026 | Morgan Stanley | main | Overweight | Overweight |
| Sep 9, 2026 | Leerink Partners | main | Outperform | Outperform |
| Sep 9, 2026 | Wells Fargo | main | Overweight | Overweight |
| Sep 9, 2026 | RBC Capital | main | Outperform | Outperform |
About Pharvaris N.V.
Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), which is in phase 3, as well as in phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant. Pharvaris N.V. was incorporated in 2015 and is headquartered in Zug, Switzerland.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Switzerland
- Website
- pharvaris.com
News
This Monolithic Power Analyst Turns Bullish; Here Are Top 4 Upgrades For Friday 
This Hilton Hotels Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday 
Pharvaris to Present Clinical and Real-World Data at the ACAAI 2026 Annual Scientific Meeting 
This Pentair Analyst Is No Longer Bearish; Here Are Top 2 Upgrades For Wednesday 
This Tesla Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday 
Two Pills, One Target: Analyst Bets on Pharvaris as Clinical Risks Fade 
This Allegion Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday 
B of A Securities Upgrades Pharvaris to Buy, Maintains Price Target to $44 
12 Health Care Stocks Moving In Wednesday's Pre-Market Session 
Reported Earlier, Pharvaris Says Lancet-Published Phase 3 Data Show Deucrictibant IR Delivered Symptom Relief In 1.28 Hours And Complete Resolution In 11.95 Hours For HAE Attacks, With NDA And MAA Under Review
Your note
Sign in to keep a note on PHVS — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ABELE STEFAN | Chief Operating Officer | Sale | Sep 14, 2026 | 39,068 |
| BJORK ELISABETH | Director | Sale | Sep 16, 2026 | 15,167 |
| GLASSMAN ROBERT R. | Director | Sale | Sep 16, 2026 | 10,500 |
| LESAGE ANNE SIMONNE J PH.D. | Officer | Sale | Sep 16, 2026 | 0 |
| LU PENG | President | Conversion of Exercise of derivative security | Sep 21, 2026 | 110,261 |
| MODIG BERNDT B.A.E | Chief Executive Officer | Conversion of Exercise of derivative security | Sep 16, 2026 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| FMR, LLC | 10.04% | 6,565,272 | 228.34M | Jun 29, 2026 |
| General Atlantic, L.P. | 10.02% | 6,550,757 | 227.84M | Jun 29, 2026 |
| Foresite Capital Management IV, LLC | 7.31% | 4,778,581 | 166.20M | Jun 29, 2026 |
| venBio Partners LLC | 7.10% | 4,643,430 | 161.50M | Jun 29, 2026 |
| Viking Global Investors, L.P. | 5.59% | 3,653,310 | 127.06M | Jun 29, 2026 |
| Eqt Fund Management S.a R.l. | 5.24% | 3,424,609 | 119.11M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund | 2.10% | 1,373,193 | 47.76M | Aug 30, 2026 |
| VANGUARD SPECIALIZED FUNDS-Vanguard Health Care Fund | 1.78% | 1,165,414 | 40.53M | Jul 30, 2026 |
| Fidelity Select Portfolios-Select Health Care Portfolio | 1.22% | 800,000 | 27.82M | Aug 30, 2026 |
| Fidelity Securities Fund-Fidelity Small Cap Growth Fund | 0.99% | 644,591 | 22.42M | Jul 30, 2026 |
| Fidelity Advisor Series VII-Fidelity Advisor Health Care Fund | 0.61% | 400,000 | 13.91M | Aug 30, 2026 |
| Fidelity Mt. Vernon Street Trust-Fidelity Growth Company K6 Fund | 0.61% | 399,479 | 13.89M | Aug 30, 2026 |